Danco Laboratories and GenBioPro, the primary producers of mifepristone, raced to the U.S. Supreme Court over the weekend with emergency filings. They seek to overturn a fresh ruling from the 5th U.S. Circuit Court of Appeals that slams the door on mailing the abortion pill nationwide. Chaos. Immediate confusion for patients, providers, pharmacies. That’s the fallout from Friday’s decision, which revives an in-person pickup mandate the FDA scrapped years ago.
The 5th Circuit panel—unanimous, conservative—sided with Louisiana’s challenge. The state sued the FDA, claiming its 2023 move to allow mail delivery ignored risks like sepsis and hemorrhage. Judges found Louisiana likely to win on merits. So they stayed the FDA’s rule pending full litigation. Mifepristone, first pill in a two-drug regimen, powers about two-thirds of U.S. abortions. Mail access exploded post-Dobbs, when the Supreme Court axed Roe v. Wade in 2022. Nearly half the states now ban or curb the procedure. Telehealth prescriptions bypass borders, fueling fights like this one.
Danco’s lawyers didn’t mince words. “The Order results in immediate chaos,” they wrote in a motion for a temporary stay at the appeals court, which they also requested. “It is now unclear whether pharmacies nationwide may still dispense mifepristone to women tonight.” GenBioPro CEO Evan Masingill called the ruling alarming. “This court’s decision to ignore the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents,” he said, per CNN. Danco echoed that in its Supreme Court application: the appeals decision “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” (Investing.com)
Rewind to the origins. FDA approved mifepristone in 2000 under strict rules: in-person only. In 2016 and 2021, it eased limits—longer gestation, fewer office visits. Then 2023: full mail-order green light via pharmacies, no doctor handoff needed. Safety data backed it—millions of doses, low complication rates. But post-Dobbs, states pounced. Louisiana Attorney General Liz Murrill, a Republican, filed suit last year after Trump’s FDA wouldn’t revive old rules administratively. A lower court paused the case earlier this year for agency review. Friday, the 5th Circuit lifted that pause and imposed its own nationwide block. (Politico)
Supreme Court watchers see echoes of 2024. Then, justices unanimously rebuffed anti-abortion doctors challenging FDA approval outright—for lack of standing. Danco and FDA prevailed. Yet here we are again. States like Missouri, Kansas, Idaho now lead a parallel suit on mail rules. Drugmakers argue the 5th Circuit overreached, second-guessing FDA science. Louisiana counters: agency ignored dangers, especially without checks on who gets the pills. Abusive partners ordering online? Real fears, say critics. (Reuters)
But. Providers scramble already. In legal states, telehealth was routine. Rural women, abuse survivors, travelers—no more mail. Clinics brace for surges; some pivot to alternatives like misoprostolone alone, less effective. Guttmacher Institute’s Kelly Baden called it “the most sweeping threat to abortion access since” Dobbs. Family Research Council’s Tony Perkins cheered: “great news for the unborn.” Trump-era FDA review drags on, possibly past midterms. (AP News)
Legal paths fork. Supreme Court could grant an administrative stay fast—shadow docket style. Or schedule arguments before summer break. Full 5th Circuit rehearing? Possible, but drugmakers bypassed it for D.C.’s top bench. FDA might join, defending its authority. Stakes tower over pharma regulation. If courts dictate dispensing, what’s next for opioids, vaccines? Mifepristone fuels most revenue for Danco (Mifeprex brand) and GenBioPro (generic). Blockade hits wallets hard. (Washington Post)
And politics simmers. Midterms loom. Abortion ballots in several states. This lands square in the crossfire. Providers adapt—stockpiling, courier services where legal. But nationwide chill spreads doubt. Patients delay. One OB-GYN group chief learned mid-presentation Friday; her slide deck suddenly outdated. (New York Times)
Danco’s Supreme Court ask: immediate halt, then full review. GenBioPro followed suit. Justices—six conservatives—face pressure. 2024 unanimity on standing doesn’t bind here; states have stronger claims. Yet FDA deference runs deep, Chevron or no. Chaos reigns until they act. Patients wait. Industry watches.
WebProNews is an iEntry Publication